Abbott's Exact Sciences buy, Blackstone and TPG's Hologic acquisition, and Water's BD transaction could herald a busy 2026 ...

Last week, readers were most interested in a story about the reasons behind the rapid adoption of BioMérieux's SpotFire syndromic qPCR instrument.

The US Food and Drug Administration cleared a number of molecular tests and immunoassays, as well as a clinical chemistry and a cellular deformation test.

NEW YORK – Increased commercial alliances, regulatory clearances, and academic evaluations helped advance digital pathology into the mainstream in 2025 and toward further adoption in the coming years.

Over the year multiple clinical trial readouts validated the use of MRD for multiple indications, while companies in the space began to consolidate.

The new financial agreements include $5 million of new term-loan proceeds to strengthen liquidity and funding for continued investment in product development.

The deal gives clinicians in PathNet's national lab network access to Valar's AI-powered Vesta diagnostic portfolio for non-muscle invasive bladder cancer.

NEW YORK – Fulgent Genetics announced on Monday that it has entered into a definitive agreement to acquire lab service provider StrataDx, as well as certain assets of Bako Diagnostics. Fulgent said it ...

NEW YORK – Germany's Paul Ehrlich Institut said this week that it has been designated by the European Commission as an EU reference laboratory for in vitro diagnostics medical devices for detecting ...